BLACK LIVES MATTER
Join us and donate
The premier IDE for R
RStudio anywhere using a web browser
Put Shiny applications online
Shiny, R Markdown, Tidyverse and more
Do, share, teach and learn data science
An easy way to access R packages
Let us host your Shiny applications
The premier software bundle for data science teams
RStudio for the Enterprise
Connect data scientists with decision makers
Control and distribute packages
RStudio Public Package Manager
RStudio Server Pro
RStudio Package Manager
The Role of R in Drug Discovery, Research, and Development
July 18, 2019
The analytics required to bring a novel molecule to market involves the collective effort of hundreds of quantitative scientists, with incredibly diverse training, tools and workflows. In this talk, speakers from Roche/Genentech will discuss the diverse ways R can be used in different stages of the pharma lifecycle, spanning research and discovery, through to development and market access.
Michael Lawrence - Scientist, Genentech Research and Early Development
Adapting to the rapidly changing requirements of science requires collaborative software development across the enterprise, industry and field. The principles of open and inner source provide an effective model of collaboration that breaks down silos through decentralized, bottom-up participation. We will present a framework for accommodating grassroots development within a traditional corporate structure.
Sebastian Wolf - Scientific Software Developer, Roche Diagnostics
QA processes in Roche Diagnostics are dependent on statistical evaluations. As such evaluations follow certain standard operating procedures, the biostats department decided to enable users doing them by themselves. The R-Shiny app bioWARP brings standard procedures such as linear regression or equivalence tests to people who cannot code R. It saves them time they would have spent consulting a Biostatistician or using validated Excel sheets.
Adrian Waddell - Data Analyst, Roche Pharmaceutical
Using R to generate the data analysis results of clinical trials to be included in a submission with the health authorities requires a complete ecosystem of tools, processes and environments. At Roche, we are currently developing such an ecosystem and, in this presentation, I will introduce some of its components. These include: a set of R-based tools to create tables, listings and graphs (TLGs) ad-hoc; a framework to create custom interactive web-applications using shiny for exploratory analysis that support dynamic subsetting and provide reproducibility of the TLGs. Additionally, I will show a proof-of-concept project for streamlining the creation of datasets and TLGs for health authority submissions.
James Black - Associate Director, Personalised Healthcare Data Science, Roche Pharmaceutical
Modelled on the Tidyverse, Roche/Genentech built a suit of interlocking packages to abstract infrastructure and repetition from our analyses, as well as a common philosophy that underpins this ecosystem. We will also talk about how we integrated these packages into a workflow that included meta-data collection, version controlled code, and a unified online results portal. Finally, we will share our experiences, both positive and negative, introducing this new workflow and the culture and competency shift it brought with it.